Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI™ (ustekinumab-aekn) ...

Please provide your email address to receive an email when new articles are posted on . Selarsdi is approved for the treatment of plaque psoriasis, psoriatic arthritis in adults, patients aged 6 years ...

Teva Pharmaceuticals and Alvotech announced that the Food and Drug Administration has approved Selarsdi (ustekinumab-aekn) injection as interchangeable with Stelara (ustekinumab). As of April 30, 2025 ...

Toronto, ON, (January 14, 2010) -Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA® (ustekinumab) with Enbrel* (etanercept) in the treatment of ...

Stelara is a prescription medication used to treat autoimmune conditions including psoriatic arthritis and plaque psoriasis. The cost of Stelara can vary depending on factors such as the form of the ...

Patients may now switch between Otulfi and Stelara without requiring a prescription change from a health care provider. The Food and Drug Administration (FDA) has designated Otulfi ® (ustekinumab-aauz ...

Patients may now switch between Stelara and Selarsdi, in all matching presentations, without prescriber intervention. The Food and Drug Administration (FDA) has approved Selarsdi ™ (ustekinumab-aken) ...

First and Only Anti-IL-12/23 Treatment Approved for Adult Patients Living with Psoriatic Arthritis HORSHAM, Pa., Sept. 23, 2013-- Janssen Biotech, Inc., announced today that the U.S. Food and Drug ...